Gian Life Care Ltd.
Snapshot View

23.85 -0.60 ▼-2.5%

27 January 2023, 04:01:00 PM
Volume: 12,184

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.gianpathlabs.com
Market Cap 24.72 Cr.
Enterprise Value(EV) 21.84 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 4.23 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 5.64 Trailing Twelve Months Ending 2022-03
Industry PE 47.03 Trailing Twelve Months Ending 2022-03
Book Value / Share 13.56 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.76 Calculated using Price: 23.85
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 1.03 Cr. 10,341,527 Shares
FaceValue 10
Company Profile
The company is engaged in the business of providing diagnostic and related healthcare services. The company provides a wide range of diagnostic tests and services like patient diagnosis services, prevention, and wellness diagnosis services to patients and healthcare providers. The company caters to individual patients, hospitals, corporates and other healthcare providers. The company offers various tests including biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, histopathology, immunoassay, microbiology, molecular biology, and radiology services.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-2.45%
1 Week
-3.25%
1 Month
+7.19%
3 Month
+13.57%
6 Month
-34.30%
1 Year
-48.38%
2 Year
+115.06%
5 Year
10 Year
1 years 2022-03
Return on Equity (%) 31.16
Return on Capital Employed (%) 44.24
Return on Assets (%) 18.95

Balance Sheet View Details >>

Particulars 1 years 2022-03 Rs. Cr.
Shh. Funds 14
Non Curr. Liab. 2
Curr. Liab. 7
Minority Int.
Equity & Liab. 23
Non Curr. Assets 13
Curr. Assets 10
Misc. Exp. not W/O
Total Assets 23

Profit Loss View Details >>

Particulars 1 years 2022-03 Rs. Cr.
Net Sales 16
Other Income 1
Total Income 16
Total Expenditure -9
PBIDT 7
Interest -1
Depreciation 0
Taxation -1
Exceptional Items
PAT 4
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 4
Adjusted EPS 4

Cash Flow View Details >>

Particulars 1 years 2022-03 Rs. Cr.
Cash Fr. Operatn. 6
Cash Fr. Inv. -4
Cash Fr. Finan. 1
Net Change 2
Cash & Cash Eqvt 5

Shareholding Pattern View Details >>

6 Qtrs 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2022-03 (%) 2022-09 (%)
Promoter 69.87 69.87 69.87 69.87 64.95 60.77
Public 30.13 30.13 30.13 30.13 35.05 39.23
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 21 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Dear Sir/Madam We enclose herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the period ended December 31 2022 for your information and record.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED
Mon, 14 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday November 14 2022
Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 14th November 2022 has inter-alia considered and approved the following:-1. Standalone and Consolidated Financial Results of the Company for the half year ended 30th September 2022. (Signed Copy along with Limited Review Report enclosed). The Board Meeting commenced at 06:00 P.M and concluded at 07.50 P.M.The above information shall also be made available on the website of the Company at https://gianlifecare.org.You are requested to kindly take the above information in your records.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED
Mon, 14 Nov 2022
Standalone And Consolidated Financial Results Of The Company For The Half Year Ended 30Th September 2022
Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 14th November 2022 has inter-alia considered and approved the following:-1. Standalone and Consolidated Financial Results of the Company for the half year ended 30th September 2022. (Signed Copy along with Limited Review Report enclosed). The Board Meeting commenced at 06:00 P.M and concluded at 07.50 P.M.The above information shall also be made available on the website of the Company at https://gianlifecare.org.You are requested to kindly take the above information in your records.

Technical Scans View Details >>

Fri, 27 Jan 2023
High Increase in 1 Month High Increase in 1 Month
High Increase in 3 Months High Increase in 3 Months
High Decrease in 6 Months High Decrease in 6 Months
High Decrease in 1 Year High Decrease in 1 Year
High Increase in 2 Years High Increase in 2 Years

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Gian Life Care Ltd.

What is Gian Life Care share price?

Can I buy Gian Life Care shares now?

What is the Market Cap of Gian Life Care?

What are the key metrics to analyse Gian Life Care?

What is the 52 Week High and Low of Gian Life Care?

What is the trend of Gian Life Care share price?